Techniques and methods

Construction and evaluation of IgG antibody Fc combinational mutation library with mammalian cell surface display system

  • Mi ZHANG ,
  • Shujun LIU ,
  • Fubin LI ,
  • Yan ZHANG
Expand
  • Shanghai Institute of Immunology; Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Basic Medical Sciences, Shanghai 200025, China
LI Fubin, E-mail: fubin.li@sjtu.edu.cn.
ZHANG Yan, E-mail: yanzhang09@sjtu.edu.cn

Received date: 2021-12-01

  Accepted date: 2022-04-25

  Online published: 2022-04-28

Supported by

National Natural Science Foundation of China(31861143030);Shanghai Science and Technology Commission Project(19431902900);Innovative Research Team of High-Level Local Universities in Shanghai(SSMU-2DCX20180100)

Abstract

Objective

·To establish an efficient method to obtain a high throughput mammalian cell surface display library of IgG antibody Fc combined mutations based on the screening results of the single point mutation library and the introduction of combined mutations by multiple degenerate primers.

Methods

·Multiple degenerate primers were designed according to the mutated amino acids at 233?240 of EU numbering with high affinity to Fcγ receptor IIB screened by fluorescence-activated cell sorting from the single point mutation library; the DNA fragments containing combined mutations were obtained through PCR by using the degenerate primers mixed with equal proportion, or according to the proportion of mutation diversity; the recombinant enzyme was used to ligate the fragment to the vector in one step and then transformed into E. coli DH5α, and the plasmid library was obtained. The plasmid library was used to transfect Pheonix cells to prepare retroviruses, and then 3T3 cells were infected with the retroviruses to obtain mammalian cell library that expressed Fc mutations on the surface. Flow cytometry was used to analyze the transfection efficiency of Pheonix cells to package retroviruses and the infection efficiency of 3T3 cells by the retroviruses. The quality of the plasmid library and the cell library was evaluated by next generation sequencing (NGS).

Results

·According to the point mutation library screening results, 32 degenerate primers were designed, which could cover all desired combined mutations, and the actual library diversity was 3.6 times that of the expected library (41 600/11 520). The results of NGS showed that the plasmid library obtained by using proportionally mixed primers according to the primer diversity had better homogeneity and integrity, and could cover 99.58% of the expected combinational mutations (11 472/11 520). Sanger sequencing results showed that 3 sequences among 10 sequences were the expected mutations, which were consistent with the diversity calculated during degenerate primers design. Flow cytometry showed that the transfection efficiency of Pheonix cells was 51.6%, and the infection efficiency of 3T3 cells was 47.4%. NGS results showed that the cell library could cover 85.92% of the expected combinational mutations (9 898/11 520).

Conclusion

·Based on the amino acid mutations screened from the single point mutation library, multiple degenerate primers were designed, and then through PCR, plasmid transfection and retrovirus infection, an IgG Fc combined mutation plasmid library and mammalian cell surface display library with more than 85% coverage of the expected combined mutations can be obtained efficiently at low cost.

Cite this article

Mi ZHANG , Shujun LIU , Fubin LI , Yan ZHANG . Construction and evaluation of IgG antibody Fc combinational mutation library with mammalian cell surface display system[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(4) : 510 -517 . DOI: 10.3969/j.issn.1674-8115.2022.04.014

References

1 CHEN D, ZHAO Y J, LI M Y, et al. A general Fc engineering platform for the next generation of antibody therapeutics[J]. Theranostics, 2021, 11(4): 1901-1917.
2 KAPLON H, MURALIDHARAN M, SCHNEIDER Z, et al. Antibodies to watch in 2020[J]. mAbs, 2020, 12(1): 1703531.
3 MULLARD A. FDA approves 100th monoclonal antibody product[J]. Nat Rev Drug Discov, 2021, 20(7): 491-495.
4 SHIELDS R L, NAMENUK A K, HONG K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR[J]. J Biol Chem, 2001, 276(9): 6591-6604.
5 RICHARDS J O, KARKI S, LAZAR G A, et al. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells[J]. Mol Cancer Ther, 2008, 7(8): 2517-2527.
6 SONDERMANN P, KAISER J, JACOB U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures[J]. J Mol Biol, 2001, 309(3): 737-749.
7 LIU R N, OLDHAM R J, TEAL E, et al. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment[J]. Antibodies (Basel), 2020, 9(4): 64.
8 NORDSTROM J L, GORLATOV S, ZHANG W J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties[J]. Breast Cancer Res, 2011, 13(6): R123.
9 MASON D M, WEBER C R, PAROLA C, et al. High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis[J]. Nucleic Acids Res, 2018, 46(14): 7436-7449.
10 WERNERSSON R. Virtual ribosome: a comprehensive DNA translation tool with support for integration of sequence feature annotation[J]. Nucleic Acids Res, 2006, 34(web server issue): W385-W388.
11 LAZAR G A, DANG W, KARKI S, et al. Engineered antibody Fc variants with enhanced effector function[J]. Proc Natl Acad Sci USA, 2006, 103(11): 4005-4010.
12 MIMOTO F, KATADA H, KADONO S, et al. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa (R131) and FcγRIIa (H131)[J]. Protein Eng Des Sel, 2013, 26(10): 589-598.
13 SMITH G P. Phage display: simple evolution in a petri dish (Nobel lecture)[J]. Angew Chem Int Ed Engl, 2019, 58(41): 14428-14437.
14 LERNER R A. Manufacturing immunity to disease in a test tube: the magic bullet realized[J]. Angew Chem Int Ed Engl, 2006, 45(48): 8106-8125.
15 NADEEM T, KHAN M A, IJAZ B, et al. Glycosylation of recombinant anticancer therapeutics in different expression systems with emerging technologies[J]. Cancer Res, 2018, 78(11): 2787-2798.
16 BEERLI R R, BAUER M, BUSER R B, et al. Isolation of human monoclonal antibodies by mammalian cell display[J]. Proc Natl Acad Sci USA, 2008, 105(38): 14336-14341.
17 ZHANG J, ZHANG X A, LIU Q, et al. Mammalian cell display for rapid screening scFv antibody therapy[J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(10): 859-866.
18 BRUUN T H, GRASSMANN V, ZIMMER B, et al. Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins[J]. mAbs, 2017, 9(7): 1052-1064.
Outlines

/